Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept Effect on Ocular Perfusion in AMD
NCT03804099Phase 4Completed
- Sponsor
- Kepler Universitätsklinikum
- Start
- Mar 2017
- Primary completion
- Mar 2018
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aflibercept in neovascular age-related macular degeneration (NVAMD), sponsored by Kepler Universitätsklinikum. Primary endpoint: Mean blur ratio (LSFG) at 12 weeks. Started Mar 2017; status: completed.
02
Drugs
aflibercept
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT03804099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03804099.